Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rush University Medical Center Testing Magnetic Stimulation for Depression

22.11.2004


Psychiatrists at Rush University Medical Center are testing a noninvasive technique that uses repeated short bursts of magnetic energy to stimulate nerve cells in the brain to treat major depression. The therapy is called Transcranial Magnetic Stimulation (TMS), and Rush is enrolling patients in a clinical trial to determine if TMS is safe and effective.



"We think that this is landmark research for a new antidepressant treatment," said Dr. Philip Janicak, Rush psychiatrist and the principal investigator for the study at Rush. "If proven effective, TMS could signal a radical shift in our approach to treating major depression." Depression is commonly treated with antidepressants and other pharmaceuticals, psychotherapy and electroconvulsive therapy (ECT) for severe cases when patients do not respond to other therapies.

This study focuses on patients who have not responded to antidepressant medication for their depression. Rush is one of 16 academic medical centers participating in this nationwide clinical trial. Smaller preliminary studies using TMS produced an antidepressant effect and led to the current research project. Information from this larger, more rigorous trial will be provided to the U.S. Food and Drug Administration to support regulatory clearance of the Neuronetics TMS System for use in treating depression.


The double-blind study will test the new treatment while controlling for this so-called "placebo effect." Janicak explained that this study, which includes a placebo (or sham) treatment, is needed because some patients improve simply due to the added attention they receive in a research study. Neither the doctor nor the patient will know which treatment, the active TMS or the placebo, is being used. After the initial treatment phase (four to six weeks), however, patients can be given the real TMS treatment if their symptoms have not improved.

Transcranial magnetic stimulation (TMS) produces pulses of magnetic energy that are aimed at a specific portion of the brain, the left prefrontal cortex. Researchers believe the left prefrontal cortex is involved in regulating mood.

TMS produces the same amount of magnetic energy as a standard MRI machine. However, instead of helping doctors look inside the body to diagnose disease, the pulses of magnetic energy produce an electric field that researchers believe causes positive changes in mood. "The amount of energy delivered to the brain is very small and very focused," Janicak said. Patients remain fully awake during the 45-minute outpatient procedure and can go about their normal activity before and after the procedure. TMS is performed without anesthesia, and it does not cause memory loss as is sometimes found with the use of ECT. Patients who qualify for the trial will initially receive 30 sessions over a period of six weeks.

The National Institute of Mental Health reports that depression affects more than 18 million adults every year. Even with recent advances in antidepressant medications, a significant percentage of patients experience treatment-resistant or recurrent episodes of depression. Some patients cannot tolerate medications.

This new research study, which involves hundreds of patients nationwide, will be a pivotal trial. If the results of the study are positive and the TMS procedure is approved by the U.S. FDA, an entirely new treatment option for patients suffering from depression would be available.

Rush is inviting qualified patients to volunteer to participate in this study. To qualify, patients must be:

  • between 18 and 70 years old.
  • suffering from a major depressive disorder.
  • able to provide written documentation that they have been unsuccessfully treated previously with antidepressant medication.

Patients who have been diagnosed with bipolar illness (manic depression) or obsessive-compulsive disorder are not eligible to participate in the trial.

For more information or to volunteer, call 1-800-345-8707.

Mary Ann Schultz | EurekAlert!
Further information:
http://www.rush.edu

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>